Shandong Sanyuan Biotechnology Co.Ltd.

301206.CS▼2

Sanyuan Biology's 2026 interim net profit was 50.3976 million yuan, down 12.32% year-on-year

Sanyuan Biology released its 2026 interim report, with total operating revenue of 429 million yuan and net profit attributable to the parent of 50.3976 million yuan, a decrease of 12.32% compared with the same period last year. The company's net cash inflow from operating activities was 73.6372 million yuan, its asset-liability ratio was 6.46%, its gross margin was 17.59%, and diluted earnings per share was 0.25 yuan. The number of shareholders was 14,400, and the top ten shareholders held 64.74% of the total share capital.

301206.CS ▼

Jiemian·22dRead more →

301206.CS▲

Sanyuan Biology plans to participate in capital increase project of Sinoma Synthetic Crystals Research Institute Shandong Company

Sanyuan Biology announced that it intends to participate as an intended investor in the capital increase project of Sinoma Synthetic Crystals Research Institute (Shandong) Company, with a proposed investment amount of no more than 30 million yuan. Sinoma Synthetic Crystals Research Institute (Shandong) Company plans to raise no more than 200 million yuan through capital increase and share expansion, focusing on the infrared optical materials and products industry. Its main products include multispectral CVD zinc sulfide, elemental-grade zinc sulfide, CVD zinc selenide, hot-pressed magnesium fluoride and other special infrared optical materials, which are widely used in infrared imaging, photoelectric detection, security monitoring, intelligent driving and other fields. Sanyuan Biology said that this investment is based on the steady development of its core main business, further deepening its layout in the field of optical materials and devices, and cultivating a medium- and long-term second growth curve for the company.

301206.CS ▲

证券时报·31dRead more →

301206.CS2

Sanyuan Bio plans 30 million yuan capital increase in Youwei Optoelectronics to cultivate a second growth curve

Sanyuan Bio plans to use its own funds to increase capital in Shenzhen Youwei Optoelectronics Technology Co., Ltd. by 30 million yuan. After the transaction, it will hold a 10.7143% stake in Youwei Optoelectronics. Youwei Optoelectronics was established in July 2023 and is a research and development startup. It is engaged in CLBO crystals and their all-solid-state lasers, and has developed a technical route for growing YIG bulk single crystals using the optical floating zone method. However, it has not yet achieved profitability. Its 2025 operating revenue was 11.3588 million yuan, with a net loss of 7.5395 million yuan. Sanyuan Bio stated that this investment is aimed at cultivating a medium- to long-term second growth curve for the company while maintaining its core business in healthy sweetening ingredients. The investment amount accounts for 0.68% of the company's latest audited total assets, making it a prudent investment attempt with controllable risks. The announcement also cautioned that the target company may face multiple risks, including failure in technology research and development, industrialization falling short of expectations, loss of core personnel, and investment impairment.

301206.CS

全部为公司自有资金·74dRead more →